Literature DB >> 14746698

[Acetylsalicylic acid consumption in patients with diabetes mellitus].

Enric Esmatjes1, Conxa Castell, Josep Franch, Emma Puigoriol, Rubén Hernáez.   

Abstract

BACKGROUND AND
OBJECTIVE: Acetylsalicylic acid (ASA) has been recommended for primary (PP) and secondary prevention (SP) of cardiovascular disease (CVD) in diabetic patients. The consumption of ASA among Catalan diabetic people is described here. SUBJECTS AND
METHOD: We analyzed 1,718 questionnaires administered to members of the Catalonia's Diabetic Association. ASA intake, history of CVD and medical advice about the use of ASA were evaluated.
RESULTS: ASA was taken by 21% subjects (as PP in 14% and as SP in 53%). Medical advice had been received in 23% (15% as PP and 56% as SP).
CONCLUSIONS: ASA intake among diabetic patients is low in both PP and SP. Physicians should recommend its use to improve this situation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14746698     DOI: 10.1016/s0025-7753(04)74155-x

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  4 in total

1.  [Finding the right platelet anti-aggregant prescription for type-2 diabetes patients, according to the ADA 2003 criteria].

Authors:  Sandra Raméntol Teys; Vicenta Pujol Blaya; Mónica León de la Fuente; María León-Sanromà
Journal:  Aten Primaria       Date:  2006-10-31       Impact factor: 1.137

2.  [Anti-platelet treatment for all diabetic patients?].

Authors:  José Luis Torres Baile; Guacimara Ortega Sánchez
Journal:  Aten Primaria       Date:  2009-07-22       Impact factor: 1.137

Review 3.  Gastrointestinal effects of aspirin.

Authors:  Carlos Sostres; Angel Lanas
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-06-07       Impact factor: 46.802

4.  Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain.

Authors:  Antoni Sicras-Mainar; Ruth Navarro-Artieda; Javier Rejas-Gutiérrez; Jaime Fernández-de-Bobadilla; Xavier Frías-Garrido; Rafael Ruiz-Riera
Journal:  BMC Fam Pract       Date:  2007-10-17       Impact factor: 2.497

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.